By 1992 Grotendorst, who had done work at the University of South Florida and is now at the University of Miami, concluded that it was CTGF, not TGF-beta, that triggers collagen production by binding to specific cell receptors.
The breath-test technology relies on the idea that the biology of tumours can lead to the production of specific "volatile organic compounds", combinations of chemicals unlikely in a healthy person.